Velkommen til

Dansk Selskab for
Klinisk Cannabismedicin

Hvem er vi

Dansk selskab for Klinisk Cannabismedicin


Dansk Selskab for Klinisk Cannabismedicin (DSKCan) blev i 2022 stiftet som del af Lægevidenskabelige Selskaber under Lægeforeningen med det formål at afsøge mulighederne for anvendelse af cannabismedicin i patientbehandlingen og fremme evidensbaseret klinisk forskning inden for området.

Nyeste viden

Se mere
  • 8 nov
    Original: Pain Manag Nurs .

    Effect of Topical Hemp (Cannabis sativa L.) Seed Oil on Knee Osteoarthritis: A Randomized Double-Blind Controlled Trial

    Purpose, and design: Knee osteoarthritis (OA) is one of the most common and debilitating diseases, especially in the elderly. Hemp seed oil is a plant product that has been used as a food or drug since ancient times because of its anti-inflammatory and analgesic properties. Methods: A double-blind, active, placebo-controlled trial was done to assess the efficacy […]

    Læs mere
  • 8 nov
    Original: J Orthop Trauma .

    Perceptions in Orthopedic Surgery on the Use of Cannabis in Treating Pain: A Survey of Musculoskeletal Trauma Patients-Results From the Canadian POSIT Study

    Objectives: To evaluate the patient-reported expectations regarding cannabis for pain following musculoskeletal (MSK) trauma and patients’ perceptions and attitudes regarding its use. Design: A cross-sectional retrospective survey-based study. Setting: Three orthopaedic clinics in Ontario (Level-1 trauma center, Level-2 trauma center, rehabilitation clinic). Patients selection criteria: Adult patients presenting to the clinics from January 24, 2018, to March 7, 2018, […]

    Læs mere
  • 8 nov
    Original: Front Pharmacol .

    Edible cannabis for chronic low back pain: associations with pain, mood, and intoxication

    Introduction: Cannabis, commonly known for both therapeutic and intoxicating effects, is gaining accessibility on legal markets and traction as a potential alternative therapy for pain mediation, particularly in those suffering from chronic low back pain. However, the effectiveness in this population of legal market forms of cannabis, particularly commonly used edibles, is unknown. Methods: Therefore, this study […]

    Læs mere
  • 11 okt
    Original: BMJ Ment Health .

    Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers

    Background: The mental health benefits of cannabidiol (CBD) are promising but can be inconsistent, in part due to challenges in defining an individual’s effective dosage. In schizophrenia, alterations in anandamide (AEA) concentrations, an endocannabinoid (eCB) agonist of the eCB system, reflect positively on treatment with CBD. Here, we expanded this assessment to include eCBs alongside AEA […]

    Læs mere